A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment
318
Participants
Timeline
Start Date
August 30, 2013
Primary Completion Date
July 21, 2016
Study Completion Date
October 25, 2016
Conditions
Hepatitis C Virus InfectionHuman Immunodeficiency Virus InfectionChronic Hepatitis CCompensated Cirrhosis and Non-cirrhotics